Lowest-Rated Stocks NYSE:GSK GSK - GSK Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding GSK plc Please log in to your account or sign up in order to add this asset to your watchlist. $35.12 -0.18 (-0.51%) (As of 01/30/2023 12:00 AM ET) Add Compare Share Share Today's Range$35.10▼$35.6350-Day Range$33.44▼$37.9252-Week Range$28.47▼$46.97Volume4.74 million shsAverage Volume3.84 million shsMarket Capitalization$71.89 billionP/E Ratio4.30Dividend Yield3.70%Price TargetN/A ProfileAnalyst RatingsChartCompetitorsDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media GSK MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.37% of Float Sold ShortDividend StrengthStrongBased on Four FactorsSustainabilityN/ANews Sentiment0.39Based on 11 Articles This WeekInsider TradingN/AProj. Earnings Growth3.32%From $3.31 to $3.42 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.51 out of 5 starsMedical Sector155th out of 1,049 stocksPharmaceutical Preparations Industry67th out of 514 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for GSK. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.37% of the float of GSK has been sold short.Short Interest Ratio / Days to CoverGSK has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in GSK has recently decreased by 11.03%, indicating that investor sentiment is improving significantly. Previous Next 3.3 Dividend Strength Dividend LeadershipGSK is a leading dividend payer. It pays a dividend yield of 3.70%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthGSK does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of GSK is 15.93%. This payout ratio is at a healthy, sustainable level, below 75%.Dividend SustainabilityBased on earnings estimates, GSK will have a dividend payout ratio of 38.01% next year. This indicates that GSK will be able to sustain or increase its dividend. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for GSK. Previous Next 3.0 News and Social Media Coverage News SentimentGSK has a news sentiment score of 0.39. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 11 news articles for GSK this week, compared to 6 articles on an average week.Search Interest71 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 6% compared to the previous 30 days.MarketBeat Follows46 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 64% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, GSK insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 10.00% of the stock of GSK is held by insiders.Percentage Held by InstitutionsOnly 13.15% of the stock of GSK is held by institutions. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for GSK are expected to grow by 3.32% in the coming year, from $3.31 to $3.42 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of GSK is 4.30, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.19.Price to Earnings Ratio vs. SectorThe P/E ratio of GSK is 4.30, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 153.22.Price to Earnings Growth RatioGSK has a PEG Ratio of 1.22. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGSK has a P/B Ratio of 2.58. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About GSK (NYSE:GSK) StockGSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.Read More Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Stock News HeadlinesJanuary 26, 2023 | marketbeat.comHow Could GSK's RSV Vaccine Change its Valuation? (GSK)GSK's RSV vaccine could be a good earner for the company, according to outside analysts and its own predictions for the future.January 30, 2023 | americanbankingnews.comGSK (GSK) Set to Announce Quarterly Earnings on WednesdayJanuary 30, 2023 | UNKNOWN (Ad)Become an Investor in Brooklyn GinAward winning super-premium craft gin and upcoming Brooklyn distilleryJanuary 28, 2023 | americanbankingnews.comStockNews.com Upgrades GSK (NYSE:GSK) to "Strong-Buy"January 26, 2023 | marketwatch.comGSK falls Tuesday, underperforms marketJanuary 26, 2023 | marketwatch.comGSK rises Wednesday, outperforms marketJanuary 22, 2023 | americanbankingnews.comGSK plc (NYSE:GSK) Short Interest Down 22.8% in DecemberJanuary 17, 2023 | finance.yahoo.comUPDATE 1-Moderna says RSV vaccine 84% effective at preventing symptoms in older adultsJanuary 30, 2023 | UNKNOWN (Ad)Become an Investor in Brooklyn GinAward winning super-premium craft gin and upcoming Brooklyn distilleryJanuary 10, 2023 | finance.yahoo.comGSK quadruples space in Alewife lab building with new leaseJanuary 9, 2023 | stocknews.com3 Must Have Pharma Stocks in January 2023December 30, 2022 | finance.yahoo.comGSK Looking For Under-Appreciated M&A Targets, Not Trying To Be Next Roche Or AstraZenecaDecember 24, 2022 | msn.comWhy I’d buy GSK shares in 2023December 24, 2022 | seekingalpha.comGSK, Sanofi COVID booster vaccine gets approval in UKDecember 17, 2022 | msn.comMasterplan to guide future development of GSK site now completeDecember 17, 2022 | marketwatch.comGSK rises Thursday, outperforms marketDecember 17, 2022 | nasdaq.comGSK (GSK) Stock Moves -0.81%: What You Should KnowDecember 3, 2022 | msn.comBRIEF-GSK Says EMA Accepts Marketing Authorisation Application For MomelotinibDecember 3, 2022 | msn.comWhy Is Glaxo (GSK) Up 6.7% Since Last Earnings Report?December 2, 2022 | finance.yahoo.comShould You Hold GSK plc (GSK) Shares?November 22, 2022 | finance.yahoo.comUPDATE 2-GSK to stop selling blood cancer drug Blenrep in United StatesNovember 22, 2022 | finance.yahoo.comGSK to withdraw Blenrep’s U.S. marketing authorization after FDA requestNovember 14, 2022 | finance.yahoo.comGSK Touts Encouraging Data From Mid-Stage Tuberculosis Program In Drug-Susceptible PatientsNovember 9, 2022 | marketwatch.comHospital-Acquired Infection Control Market Analysis Geography Trends, Demand and Forecasts 2028| GSK, Merck, PfizerNovember 9, 2022 | barrons.comGSK Shares Drop as Cancer Drug DisappointsNovember 8, 2022 | finance.yahoo.comSpero Therapeutics Announces Closing of Exclusive License Agreement with GSK for Tebipenem HBrNovember 7, 2022 | finance.yahoo.comGSK's Conditionally Approved Blood Cancer Drug Fails On Progression-Free Survival Goal Over Standard CareSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive GSK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter. Email Address GSK Company Calendar Last Earnings11/02/2022Ex-Dividend for 1/12 Dividend11/17/2022Dividend Payable1/12/2023Today1/30/2023Next Earnings (Confirmed)2/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:GSK CUSIPN/A CIK1131399 Webwww.gsk.com Phone442080475000Fax44-20-8047-7807Employees90,096Year Founded2000Profitability EPS (Most Recent Fiscal Year)$8.16 Trailing P/E Ratio4.30 Forward P/E Ratio10.61 P/E Growth1.22Net Income$6.03 billion Net Margins37.88% Pretax Margin15.33% Return on Equity32.18% Return on Assets7.69% Debt Debt-to-Equity Ratio2.22 Current Ratio0.97 Quick Ratio0.74 Sales & Book Value Annual Sales$38.44 billion Price / Sales1.87 Cash Flow$3.60 per share Price / Cash Flow9.76 Book Value$13.62 per share Price / Book2.58Miscellaneous Outstanding Shares2,047,099,000Free Float1,842,389,000Market Cap$71.89 billion OptionableOptionable Beta0.66 Social Links Key ExecutivesEmma N. WalmsleyChief Executive Officer & Executive DirectorIain James MackayChief Financial Officer & Executive DirectorJon EllisVP & Head-Technology Business DevelopmentTony WoodChief Scientific OfficerShobie RamakrishnanChief Digital & Technology OfficerKey CompetitorsZoetisNYSE:ZTSRegeneron PharmaceuticalsNASDAQ:REGNVertex PharmaceuticalsNASDAQ:VRTXTakeda PharmaceuticalNYSE:TAKAlnylam PharmaceuticalsNASDAQ:ALNYView All CompetitorsInsiders & InstitutionsKeystone Financial Planning Inc.Bought 1,210 shares on 1/30/2023Ownership: 0.013%Traverso Chambers Private Wealth Management LLCBought 283 shares on 1/30/2023Ownership: 0.001%Kistler Tiffany Companies LLCSold 1,030 shares on 1/30/2023Ownership: 0.000%Concourse Financial Group Securities Inc.Sold 691 shares on 1/30/2023Ownership: 0.000%Carlton Hofferkamp & Jenks Wealth Management LLCSold 805 shares on 1/30/2023Ownership: 0.000%View All Institutional Transactions GSK Stock - Frequently Asked Questions Should I buy or sell GSK stock right now? 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares. View GSK analyst ratings or view top-rated stocks. How have GSK shares performed in 2023? GSK's stock was trading at $35.14 on January 1st, 2023. Since then, GSK stock has decreased by 0.1% and is now trading at $35.12. View the best growth stocks for 2023 here. Are investors shorting GSK? GSK saw a decrease in short interest in the month of December. As of December 30th, there was short interest totaling 8,430,000 shares, a decrease of 22.8% from the December 15th total of 10,920,000 shares. Based on an average trading volume of 5,660,000 shares, the days-to-cover ratio is currently 1.5 days. Approximately 0.4% of the company's stock are sold short. View GSK's Short Interest. When is GSK's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 1st 2023. View our GSK earnings forecast. How can I listen to GSK's earnings call? GSK will be holding an earnings conference call on Wednesday, February 1st at 6:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were GSK's earnings last quarter? GSK plc (NYSE:GSK) announced its quarterly earnings data on Wednesday, November, 2nd. The pharmaceutical company reported $1.09 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.90 by $0.19. The pharmaceutical company had revenue of $9.22 billion for the quarter, compared to analysts' expectations of $7.75 billion. GSK had a trailing twelve-month return on equity of 32.18% and a net margin of 37.88%. How often does GSK pay dividends? What is the dividend yield for GSK? GSK announced a quarterly dividend on Wednesday, November 2nd. Investors of record on Friday, November 18th will be paid a dividend of $0.3695 per share on Thursday, January 12th. This represents a $1.48 annualized dividend and a dividend yield of 4.21%. The ex-dividend date is Thursday, November 17th. Read our dividend analysis for GSK. Is GSK a good dividend stock? GSK (NYSE:GSK) pays an annual dividend of $1.31 per share and currently has a dividend yield of 3.71%. The dividend payout ratio is 16.05%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 38.30% next year. This indicates that the company will be able to sustain or increase its dividend. Read our dividend analysis for GSK. What guidance has GSK issued on next quarter's earnings? GSK issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $50.67 billion-$51.60 billion, compared to the consensus revenue estimate of $32.29 billion. What other stocks do shareholders of GSK own? Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA). What is GSK's stock symbol? GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK." Who are GSK's major shareholders? GSK's stock is owned by a number of institutional and retail investors. Top institutional shareholders include JTC Employer Solutions Trustee Ltd (0.88%), Douglas Lane & Associates LLC (0.10%), National Bank of Canada FI (0.02%), Keystone Financial Planning Inc. (0.01%), Natixis Advisors L.P. (0.01%) and Jacobs & Co. CA (0.01%). View institutional ownership trends. How do I buy shares of GSK? Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is GSK's stock price today? One share of GSK stock can currently be purchased for approximately $35.12. How much money does GSK make? GSK (NYSE:GSK) has a market capitalization of $71.89 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $8.16 on an earnings per share basis. How many employees does GSK have? The company employs 90,096 workers across the globe. How can I contact GSK? GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807. This page (NYSE:GSK) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.